Literature DB >> 12853325

Mitochondria as a target for neurotoxins and neuroprotective agents.

Sergey O Bachurin1, Elena P Shevtsova, Elena G Kireeva, Gregory F Oxenkrug, Sergey O Sablin.   

Abstract

Mitochondrial permeability transition pores represent a multiprotein complex that includes components of both inner and outer membrane. The pores regulate transport of ions and peptides in and out of mitochondria, and their regulation is associated with a general mechanism for maintaining Ca(2+) homeostasis in the cell and apoptosis. Various pathologic factors may induce a pathologic activation of the permeability transition and an irreversible opening of mitochondria pores. This event is a major step in the development of neurotoxicity and neurodegeneration. This paper explores the effect of MPP(+) and beta-amyloid fragment 25-35, neurotoxins that are known to generate Parkinson's-like syndrome and Alzheimer's disease, on the regulation of the mitochondrial pores. Both neurotoxins induce opening of mitochondrial pores, which is prevented by cyclosporin A, a specific inhibitor of the permeability transition. The effect of MPP(+) and beta-amyloid may be also prevented by an endogenous precursor of melatonin, N-acetylserotonin, by an anti-Alzheimer's medication tacrine, and by dimebon, which is in development as an agent for the therapy of Alzheimer's disease and other types of dementia. The paper illustrates that the effect on mitochondrial pores is an important aspect of the mechanism of neurotoxicity. Substances that may prevent opening of mitochondrial pores induced by neurotoxins may preserve the mitochondrial function and, thus, may have potential as neuroprotective agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853325     DOI: 10.1111/j.1749-6632.2003.tb07541.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  65 in total

Review 1.  Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.

Authors:  Magali Dumont; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Mechanism matters.

Authors: 
Journal:  Nat Med       Date:  2010-04       Impact factor: 53.440

4.  The rise and fall of Dimebon.

Authors:  Ilya Bezprozvanny
Journal:  Drug News Perspect       Date:  2010-10

5.  The age-related gliosis and accompanying deficit in spatial learning are unaffected by dimebon.

Authors:  Thelma R Cowley; Rodrigo Esteban González-Reyes; Jill C Richardson; David Virley; Neil Upton; Marina A Lynch
Journal:  Neurochem Res       Date:  2012-09-26       Impact factor: 3.996

Review 6.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

Review 7.  An update on treatment and prevention strategies for Alzheimer's disease.

Authors:  Judith Neugroschl; Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

Review 8.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 9.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

10.  The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments.

Authors:  Chittaranjan Andrade; Rajiv Radhakrishnan
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.